Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solara Active Pharma Sciences's Total Operating Expense for the
three
months ended in Mar. 2026 was ₹1,582 Mil. Solara Active Pharma Sciences's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹5,974 Mil.
Solara Active Pharma Sciences Total Operating Expense Related Terms
Solara Active Pharma Sciences Total Operating Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solara Active Pharma Sciences Total Operating Expense Chart
Solara Active Pharma Sciences Total Operating Expense Calculation
Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.
Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹5,974 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Operating Expense of ₹5,974 Mil mean?
Solara Active Pharma Sciences (NSE:SOLARA) has a Total Operating Expense of ₹5,974 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Solara Active Pharma Sciences and its competitors.
Is Solara Active Pharma Sciences' Total Operating Expense too high?
Solara Active Pharma Sciences' current Total Operating Expense is ₹5,974 Mil. Overall, Solara Active Pharma Sciences has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Solara Active Pharma Sciences' Total Operating Expense compare to ZTS and UTHR?
Solara Active Pharma Sciences' Total Operating Expense of ₹5,974 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Solara Active Pharma Sciences and its competitors. Solara Active Pharma Sciences's current Total Operating Expense is ₹5,974 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solara Active Pharma Sciences stock overvalued right now?
Based on GuruFocus' analysis, Solara Active Pharma Sciences (NSE:SOLARA) is currently considered Fairly Valued. The stock's GF Value™ is ₹573.73, compared to a current price of ₹536.15 — trading 6.6% below its estimated fair value. The current Total Operating Expense is ₹5,974 Mil. Solara Active Pharma Sciences' overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Solara Active Pharma Sciences (NSE:SOLARA), the current Total Operating Expense is ₹5,974 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solara Active Pharma Sciences (NSE:SOLARA) Overvalued in 2026?
Based on GuruFocus' analysis, Solara Active Pharma Sciences stock appears to be undervalued.
The current stock price of ₹536.15 is trading 6.6% below its estimated GF Value™ of ₹573.73.
GuruFocus considers Solara Active Pharma Sciences to be Fairly Valued.
Key valuation signals for NSE:SOLARA:
Total Operating Expense: ₹5,974 Mil
GF Value™: ₹573.73 vs. price of ₹536.15 (6.6% below fair value)
No single metric tells the full story. See the NSE:SOLARA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Solara Active Pharma Sciences Business Description
Solara Active Pharma Sciences Ltd is engaged in the Active Pharmaceutical Ingredients (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinoid, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant, and others. It also offers contract services, including contract development and manufacturing, and analytical services. Geographically, the company generates all of its revenue from India.
68GF Score
Get the complete analysis for NSE:SOLARA
Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOLARA has been successfully added to your 
